Professor of Cannabis Science announced to research the role of cannabis in opioid overdose treatment VANCOUVER

Professor of Cannabis Science announced

to research the role of cannabis in opioid overdose treatment

VANCOUVER, Nov. 23, 2018 /CNW/ - Examining

the potential of cannabis in addressing the opioid overdose crisis and other substance use disorders is a top priority for Dr.

M-J Milloy, a recognized leader in the field of epidemiology and the first Canopy Growth Professor of Cannabis Science at the University

of British Columbia. Initially, this professorship will lead clinical trials to explore the role cannabis can play in helping people

with opioid use disorder stay on their treatment plan.

In the first nine months of 2018, it's estimated

that 1,143 people died of a suspected opioid overdose in British Columbia.

"We need all hands-on-deck to save lives

and help people find the treatment and recovery services that will work for them long term," said Judy Darcy, Minister of

Mental Health and Addictions. "Our government has been bold and innovative in providing treatment options - based on

evidence - for people living with addiction. This first-of-its-kind professorship will lead research and clinical trials

on how cannabis products can be used to address the overdose crisis that is taking three to four lives a day."

Dr. Milloy is a research scientist at the British

Columbia Centre on Substance Use (BCCSU). As a substance use epidemiologist, his research has focused on the interrelationships

between illicit drugs and HIV, as well as the public health impact of cannabis regulation and the medical application of cannabis

and cannabinoids, especially for people living with HIV or substance use disorders.

Research shows that fewer than one-third of

people who start opioid agonist therapy (OAT), with methadone or buprenorphine/naloxone, remain in treatment after six months.

Dropping out of addiction treatment is a serious risk factor for overdose death. Findings from these clinical trials could help

identify ways to better support people with opioid use disorder with cannabis-based therapy.

Dr. Milloy's research will contribute to an

emerging body of evidence suggesting that cannabis can have a positive impact on the wellbeing of people with opioid use disorder.

This professorship was established through

funding from Canopy Growth and the Province of British Columbia. The Province invested $500,000 to the BCCSU in support of research

leading to solutions to the overdose crisis. Canopy Growth is contributing $2.5 million to UBC and BCCSU to establish the Professorship

and create an enduring legacy of research through the Canopy Growth Cannabis Science Endowment Fund.

Dr. Milloy's recent research

includes studies that have found:

Using cannabis every day

was linked to a lower risk of starting to inject drugs amongst street-involved youth

Daily cannabis use increased

likelihood that people will stay in OAT treatment

Intentional cannabis use

resulted in preceded declines in crack use among crack cocaine users

Dr. Milloy has authored

more than 150 peer-reviewed articles on the impact of policy on the health outcomes of people who use drugs.

Dr. Dermot Kelleher, Dean, Faculty of Medicine

& Vice-President, Health at UBC -

"The opioid overdose crisis demands holistic

and scientific approaches in order to develop new knowledge and strategies in response to this urgent health issue facing our society.

The new Canopy Growth Professor of Cannabis Science at UBC promises to generate much-needed evidence-based solutions that will

improve the health and well-being of British Columbians."

Dr. Mark Ware, Canopy Growth Chief Medical

"There's a clear need for significant

resources and innovative collaborative leadership from industry, government, and academia to address the overdose crisis which

continues to have a devastating impact on families and communities across Canada. Today, we acknowledge the lived experience of

those affected and proudly support this significant step in building a legacy of medical cannabis research with a goal to positively

impact those living with substance use disorders around the world. Dr Milloy is a passionate, dedicated scientist who focuses on

research that has a real-word impact, and we are thrilled UBC has selected him as the Canopy Growth Professor in Cannabis Science."

Dr. M-J Milloy, Canopy Growth Professor of

"The therapeutic benefits of cannabis

are only just beginning to be understood. Early research has shown that it could have a stabilizing impact for people with opioid

use disorder, improving their quality of life and offering a pathway to long-term treatment solutions. In the midst of an overdose

crisis, we have a scientific imperative to build upon this research. I'm grateful for the support from Canopy Growth and the Province

of BC, and their commitment towards investing in evidence-based solutions to this urgent health crisis."

Photos: For event photos following the

announcement, please visit: https://www.flickr.com/photos/bcgovphotos/

About Canopy Growth Corporation

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties

in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a

passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The

Company has operations in 12 countries across five continents. The Company is proudly dedicated to educating healthcare practitioners,

conducting robust clinical research, and furthering the public's understanding of cannabis, and through its partly owned subsidiary,

Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through

partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and

building a portfolio of stable investments in the sector. From our historic public listing on the Toronto Stock Exchange and New

York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained

in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop

Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few.

Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including

over 500,000 square feet of GMP certified production space. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements

This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation

Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation.

Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans",

"expects" or "does not expect", "is expected", "estimates", "intends", "anticipates"

or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions,

events or results "may", "could", "would", "might" or "will" be taken, occur

or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which

may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from

any future results, performance or achievements expressed or implied by the forward-looking statements or information contained

in this news release. Examples of such statements include statements with respect to medical research initiatives and partnerships.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance,

prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including

the Company's ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks

contained in the Company's annual information form dated June 28, 2017 and filed with Canadian securities regulators available

on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used

in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance

should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames

or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date

of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking

information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

SOURCE Canopy Growth Corporation

View original content: http://www.newswire.ca/en/releases/archive/November2018/23/c3974.html

For further information: Media contact: Ministry of Mental

Health and Addictions Communications, 778-587-3237 (media line); British Columbia Centre on Substance Use, kevin.hollett@bccsu.ubc.ca,

778-918-1537; Contact: Aly-Khan Virani, alykhan.virani@canopygrowth.com, 236-688-5123; Investor Relations, Tyler Burns, Tyler.Burns@canopygrowth.com,

855-558-9333 ext. 122; Director: Bruce Linton, tmx@canopygrowth.com